Navigation Links
Biomarker may be an early predictor of advanced breast cancer
Date:11/5/2007

CINCINNATIResearchers have identified a molecule that may be more accurate than existing biological signposts used to predict which breast cancers will develop into advanced forms of the disease.

Detailed Oct. 24, 2007, in an early online edition of the International Journal of Cancer, the discovery could one day influence therapy decisions and prevent patients from unnecessarily undergoing aggressive cancer treatments.

When diagnosing breast cancer, pathologists currently look for elevated levels of three standard molecules known to make tumors grow in the breast. These moleculesestrogen receptor (ER), progesterone receptor (PR) and HER2are used as biomarkers for diagnosis and individually detect only a fraction of breast cancers.

The problem with these biomarkers is that many of them are present at some level in the normal breast, says Georg Weber, MD, PhD, lead investigator of the new study and associate professor of pharmacy at the University of Cincinnati. In addition, they are surface molecules that support growth so they are not necessarily a good predictor of tumor metastasis.

Weber and his team have identified a molecule, osteopontin-c, that is absent from the normal breast and appears to more accurately predict breast cancer that will become metastatic and spread to distant organs from the original tumor site.

In normal levels, osteopontin is a protein used by the immune system to help cells move and migrate. There are three forms of osteopontina, b and cwhich are formed by splicing, or cutting and pasting, ribonucleic acid (RNA) molecules to make variations of the original gene. Osteopontin-a is the normal form that helps with immune functions. Little is known about osteopontin-b, but if present its levels are very low. Osteopontin-c is the molecule Weber and his team discovered is a good biomarker of breast cancer.

In a two-year evaluation of 178 breast tumors, normal and abnormal tissue samples, they found that osteopontin-c was present in 78 percent of cancers and in 36 percent of the surrounding tissues. It was not detected at all in normal tissues.

In 56 breast cancers, 20 were positive and 36 were negative for estrogen receptor, 19 were positive and 37 were negative for progesterone receptor, and 26 were positive for HER2 with 30 negative.

Osteopontin-c was present in a substantially higher number of breast cancers than the three biomarkers traditionally used to diagnose breast cancer, says Weber. We also found that the cancers containing osteopontin-c correlated with a higher tumor grade, meaning they were more likely to become aggressive cancer.

If we know that this molecule is not present in a patient with breast cancer, its more likely that we can treat them with conservative therapy rather than breast surgery, hormone therapy or chemotherapy because we know its less likely to metastasize, he adds. On the other hand, if we know that a patient has this molecule early in their diagnosis, we can treat it more aggressively because we know their cancer is likely to become invasive.


'/>"/>

Contact: Jamie Davis Kaun
jamie.davis@uc.edu
513-558-4625
University of Cincinnati
Source:Eurekalert

Related medicine news :

1. First biomarker discovered that predicts prostate cancer outcome
2. Penn School of Medicine receives $2.3 million to study biomarkers of cigarette smoke exposure
3. Study makes progress in zoning in on biomarkers for better colon cancer treatment
4. New Ovarian Cancer Biomarker Research Act Introduced
5. Mayo Clinic study points to a possible biomarker for colon cancer in people 50 and under
6. Singulex Announces Presentation on Monitoring of Cardiac Biomarker to Assess Transient Myocardial Ischemia at the American Heart Association Scientific Sessions
7. Pot bellies linked to early signs of cardiovascular disease
8. Eye-staining technique offers early detection for dry eye syndrome
9. Early Weight Loss in Women Linked to Dementia
10. Isolation of a new gene family essential for early development
11. U of M study: Early treatment can reverse heart damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... 2017 , ... “The Inn at the Mill”: a story of love and redemption, hope ... become happy and content. , “The Inn at the Mill” is the creation of ... and Vermont and is now living in Berks County on Crow Hill. The ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Some Infallible Characteristics of Christ”: ... Infallible Characteristics of Christ” is the creation of published author, Rev. Dr. Robert W. ... for thirteen years, a preacher for over nineteen, a pastor for over fifteen years. ...
(Date:1/22/2017)... ... January 22, 2017 , ... "Photo Cloud allows FCPX users to add ... slideshow with complete ease," said Christina Austin - CEO of Pixel Film Studios. ... FCPX timeline. Presets include scenes with one, three, four or five focus ...
(Date:1/21/2017)... ... ... the perfect set of tools for video editors that want to create the illusion of ... CEO of Pixel Film Studios. , Video editors using ProDOF can add realistic depth ... focus from one area into the next. ProDOF comes with 0.5 second, 1.0 second, ...
(Date:1/21/2017)... ... January 21, 2017 , ... Northern California ... has recently joined their multi-specialty medical group. The dermatology practice provides general dermatologic ... “We’re excited to add this excellent dermatology practice to our group’s medical services,” ...
Breaking Medicine News(10 mins):
(Date:1/22/2017)... Saudi Arabia , January 22, 2017 ... US and UAE discuss the ... at the World Economic Forum   "The management and delivery of ... and powered by artificial intelligence and this trend is going to get bigger ... the Future, at the concluding day of the 47 th Annual Meeting ...
(Date:1/21/2017)... 2017 According to a new market research ... R&D, Compliance, SCM), Component (Software, Service), Delivery (On premise, Cloud), End ... by MarketsandMarkets, the market is expected to reach USD 24.73 Billion ... of 13.3% during the forecast period. ... ...
(Date:1/21/2017)... Research and Markets has announced the addition of the ... Administration, End User - Forecast to 2025" report to their ... The Global ... of around 7.8% over the next decade to reach approximately $330.70 ... global markets for Advanced Drug Delivery across all the given segments ...
Breaking Medicine Technology: